Results 91 to 100 of about 119,863 (250)

Mapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience

open access: yesAdvanced Healthcare Materials, EarlyView.
Cerebral organoids are transforming brain research, yet the field remains fragmented. This comprehensive systematic review maps 738 studies published between 2014 and 2024 to uncover trends, gaps, and opportunities across neuroscience. Introducing OrganoidMap—an interactive, open‐access platform to explore and compare models—this work enables ...
Anna Wolfram   +10 more
wiley   +1 more source

Relatively high interest but limited active engagement in HIV cure research: Awareness, interest, and information-seeking among affected communities in the Netherlands

open access: yesJournal of Virus Eradication
Background: Community engagement is important for inclusive HIV cure development. This study evaluates current engagement in HIV cure research among affected communities in the Netherlands by analyzing awareness, interest, and information-seeking ...
Maaike A.J. Noorman   +6 more
doaj   +1 more source

The Long Noncoding RNA HEAL Regulates HIV-1 Replication through Epigenetic Regulation of the HIV-1 Promoter. [PDF]

open access: yes, 2019
A major challenge in finding a cure for HIV-1/AIDS is the difficulty in identifying and eradicating persistent reservoirs of replication-competent provirus.
Chang, Kungyen   +11 more
core   +1 more source

TRMT6‐Mediated m1A Modification of CDK9 mRNA Is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang   +12 more
wiley   +1 more source

HIV cure research contributions from Africa in the last three decades

open access: yesFrontiers in Immunology
IntroductionThe HIV epidemic in Africa is characterized by extensive viral subtype diversity and human genetic heterogeneity which influence disease outcomes; amidst the co-morbidities that modulate HIV reservoirs and immune responses.
Damalie Nakanjako   +14 more
doaj   +1 more source

Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study

open access: yesVaccines, 2020
HIV cure-related clinical trials (HCRCT) with analytical antiretroviral treatment interruptions (ATIs) have become unavoidable. However, the limited benefits for participants and the risk of HIV transmission during ATI might negatively impact physicians’
Christel Protiere   +9 more
doaj   +1 more source

Gold Ash: Contested yet Immortal, The Exceptional Potency of Burmese Alchemy [PDF]

open access: yes, 2019
‘Gold ash’ (shway pya), a substance Burmese alchemists produce through a complex process of the combination and burning of metals, is considered by many Burmese as the most potent medical ingredient existing in the country. In this article, I explore the
Coderey, Céline
core   +1 more source

A Nanoparticle‐Integrated Complete Manufacturing Pipeline of Chemically Engineered Exosomes

open access: yesAdvanced Science, EarlyView.
We report a novel manufacture technology of chemically engineered exosomes. The four steps of manufacturing, i.e., biogenesis, loading, isolation, and storage, are integrated by the use of a nanoparticle. The manufacture technology incorporates three innovative components, i.e., a new nano‐bio effect, a new composite nanoparticle, and a new isolation ...
Xiaowei Wen   +13 more
wiley   +1 more source

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial [PDF]

open access: yes, 2017
Background : By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%.
Alland, D   +35 more
core   +2 more sources

Recommendations for Implementing Hepatitis C Virus Care in Homeless Shelters: The Stakeholder Perspective. [PDF]

open access: yes, 2020
Compared with the general population, homeless individuals are at higher risk of hepatitis C infection (HCV) and may face unique barriers in receipt of HCV care.
Anderson, August   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy